![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26439-26447, September 10, 1999
,
¶
From the
Cell Biology and Metabolism
Branch, NICHD, National Institutes of Health,
Bethesda, Maryland 20892 and § Department of Internal
Medicine and Medical Therapy, Internal Medicine and Medical
Oncology, University of Pavia Medical School and IRCCS Policlinico
S. Matteo, 27100 Pavia, Italy
| |
ABSTRACT |
|---|
|
|
|---|
Hereditary hyperferritinemia-cataract
syndrome (HHCS) is a novel genetic disorder characterized by
elevated serum ferritin and early onset cataract formation. The
excessive ferritin production in HHCS patients arises from aberrant
regulation of L-ferritin translation caused by
mutations within the iron-responsive element (IRE) of the
L-ferritin transcript. IREs serve as binding sites for iron
regulatory proteins (IRPs), iron-sensing proteins that regulate
ferritin translation. Previous observations suggested that each unique
HHCS mutation conferred a characteristic degree of hyperferritinemia
and cataract severity in affected individuals. Here we have measured
the in vitro affinity of the IRPs for the mutant IREs and
correlated decreases in binding affinity with clinical severity.
Thermodynamic analysis of these IREs has also revealed that although
some HHCS mutations lead to changes in the stability and secondary
structure of the IRE, others appear to disrupt IRP-IRE recognition with
minimal effect on IRE stability. HHCS is a noteworthy example of a
human genetic disorder that arises from mutations within a
protein-binding site of an mRNA cis-acting element. Analysis of the
effects of these mutations on the energetics of the RNA-protein
interaction explains the phenotypic variabilities of the disease state.
Several reports have described a new autosomal dominant disorder
called hereditary hyperferritinemia-cataract syndrome
(HHCS)1 (1-12). This
condition is characterized by a combination of elevated levels of serum
ferritin and congenital nuclear cataract. Human ferritin is composed of
two different types of subunit (H-ferritin and L-ferritin),
although the relative proportion of each subunit in the ferritin
copolymer varies among tissues (13). Through the use of monoclonal
antibodies specific for either H- or L-ferritin, the excess
serum ferritin in HHCS patients has been shown to be predominantly
L-ferritin (3, 7). A close relationship has also been
established between monocyte L-ferritin content and serum
ferritin concentration (7), suggesting that the excess production of
L-ferritin in cells is directly responsible for the
hyperferritinemia. Although serum ferritin is thought to reflect body
iron stores, individuals with HHCS do not appear to suffer from iron
overload (1, 2).
The expression of both H-ferritin and L-ferritin is
normally regulated according to intracellular iron concentration by
means of iron-responsive elements (IREs) that are found within the
5'-untranslated regions of their transcripts (14, 15). These regulatory
elements interact with the iron regulatory proteins IRP1 and IRP2,
which are both capable of sensing cellular iron status. Under
conditions of intracellular iron depletion, both IRP1 and IRP2 bind to
IREs with high affinity. The binding of an IRP to the ferritin IRE prevents the binding of the 43 S translation initiation complex to the
transcript (16, 17) and thus blocks translation of the ferritin
protein. When intracellular iron concentrations rise, IRP1 acquires a
[4Fe-4S] cluster that prevents its association with IREs and
activates its function as a cytosolic aconitase (reviewed in Refs. 18
and 19). Under the same conditions, IRP2 is targeted for degradation by
the proteasome (20, 21). In the absence of bound IRP, the ferritin
transcript is readily translated. IREs are also found within the
transcripts of other iron uptake and iron utilization proteins and have
a highly conserved stem-loop secondary structure (Fig.
1b).
The absence of iron overload in HHCS patients suggested that the
elevated serum ferritin resulted from misregulation of
L-ferritin expression. Analysis of the
L-ferritin genetic locus in HHCS patients led to the
identification of mutations occurring within the IRE of
L-ferritin (Fig. 1a), most of them occurring as
single point mutations (2, 4, 7, 9, 11), although a double point mutation (7) and a 29-base deletion (8) have also been reported. Several of these mutations have been shown to disrupt IRE-IRP binding
in vitro, and it seems likely that the others would have similar effects, leading to increased expression of
L-ferritin in vivo. As patients with HHCS have
been characterized, however, it has become clear that not all are
equally affected by the disorder. Some patients have serum ferritin
levels more than 5-fold higher than normal and a history of severe
cataracts, whereas others have only slightly elevated serum ferritin
and are asymptomatic for cataract.
Studies of non-HHCS IRE mutations have demonstrated that some mutations
affect in vitro IRE-IRP binding affinities much more severely than others (22), so we hypothesized that all or part of the
range of severity seen among HHCS patients might arise from differences
in the ability of each mutation to disrupt IRE-IRP interactions. We
were also interested in evaluating whether HHCS mutations might affect
the affinities of IRP1 and IRP2 differently. As studies have
demonstrated, both IRP1 and IRP2 are capable of recognizing their own
unique substrates in vitro (23, 24). In an effort to
identify any correlation between HHCS severity and IRP affinity, and to
reveal any differences in the behavior of the two IRPs, we determined
the dissociation constants (KD values) for the
binding of the HHCS IREs to both IRP1 and IRP2.
The identification of the HHCS mutations has also provided us with an
opportunity to understand more precisely the structural features of the
IRE required for IRP binding. Recent NMR studies of the consensus IRE
have revealed intriguing features of its three-dimensional structure
(25-27); however, it has been difficult to ascertain the importance of
those features for IRP recognition. We have used thermal denaturation
methods to determine the effects of each HHCS mutation on the
thermodynamic stability of the IRE. Analysis of the resulting melting
curves has allowed us to identify HHCS mutations that are likely to
disrupt direct contacts between the IRE and IRPs and other mutations
located both near and distant from putative contact points whose
predominant effect is to alter IRE stability.
Synthesis of Wild-type and Mutant RNAs--
The RNAs used for
both the band-shift competition assays and thermal denaturation
experiments were prepared by T7 RNA polymerase transcription from
single-stranded DNA templates using published methods (28). A series of
94-nucleotide template DNAs were used to encode the 77-nucleotide RNAs
and were purchased from either Operon Technologies, Inc. (Alameda, CA)
or Integrated DNA Technologies (Coralville, IA). For example, the
template for the wild-type L-ferritin IRE was 5'-CTGGAAGAGA
GTCCCCGGAT CTGTTCCGTC CAAACACTGT TGAAGCAAGA GACAGACCCG CGGGACCGCC
GAACTCCTAT AGTGAGTCGT ATTA-3' (the T7 RNA polymerase
promoter region is italicized). A typical 1-ml transcription reaction
contained 40 mM Tris-HCl (pH 7.5), 20 mM
MgCl2, 5 mM dithiothreitol, 1 µM
spermidine, 0.01% Triton X-100, 2 mM each NTP, 0.2 µM DNA template, and 1.5 units/µl T7 RNA polymerase
(Life Technologies, Inc.) and was incubated at 37 °C for 3 h.
Transcribed RNAs were purified on 8% (7 M urea) polyacrylamide gels, extracted from the gel, and desalted by dialysis against a solution of 10 mM potassium phosphate (pH 7.5)
and 10 mM KCl using Spectra/Por CE 500 molecular weight
cut-off DispoDialyzers (Spectrum). All RNAs were quantitated by UV
absorbance spectroscopy and were folded prior to use by heating to
95 °C for 5 min, followed by renaturation on ice for 20 min.
Synthesis of Radiolabeled Wild-type Ferritin IRE--
Internally
33P-radiolabeled wild-type Ferritin IRE was transcribed
from the same DNA template described above. RNA was transcribed in a
25-µl transcription reaction containing 40 mM Tris-HCl
(pH 7.5), 25 mM MgCl2, 5 mM
dithiothreitol, 1 µM spermidine, 0.01% Triton X-100, 4 mM GTP, 4 mM ATP, 4 mM CTP, 0.8 mM UTP, 1.7 µM (125 µCi)
[ Band-shift Competition Experiments--
Human IRP1 and IRP2
proteins for these studies were expressed and purified as previously
reported (29). All competition reactions were prepared as follows: 0.8 pmol (40 nM) of 33P-labeled wild-type
L-ferritin IRE was mixed with either 0, 0.8, 1.6, 4.0, 8.0, or 80.0 pmol (0, 40, 80, 200, 400, or 4000 nM) of unlabeled
competitor in the presence of 5% glycerol, 0.025 units/µl RNase
inhibitor (5 Prime Calculation of Dissociation Constants KD and
KRel--
Quantitation of band-shift competition gels was
performed using a Molecular Dynamics PhosphorImager and the Molecular
Dynamics ImageQuant software package. We calculated
KD values using a method previously reported for
competition assays (30). Briefly, quantitation of the gels yielded
f0 (the fraction of radiolabeled RNA shifted in
the absence of competitor), f (the amount of radiolabeled
RNA shifted in lanes with competitor), and f1,
where f1 = f/f0. From these values, the
following equations were used to determine the apparent
KD (Kapp):
Kapp = [C]free(f1/(1 Statistical Analysis of HHCS Severity Correlations with
KRel--
Data were stored, analyzed, and reported with
the package Exstatix (Select Micro Systems, Inc., Yorktown Heights, NY)
and DeltaGraph Pro 3 (DeltaPoint, Inc., Monterey, CA). Results were expressed as a mean ± 1 S.D. unless otherwise stated. Simple and multiple linear regression and nonlinear regression analyses were employed to identify the parameters most closely related to
KRel. The correlations of ln (serum ferritin)
versus 1/KRel were statistically significant for both IRP1 (n = 37, F = 32.886, p < 0.00001) and IRP2 (n = 37, F = 29.435, p < 0.00001). The fit of
ln (max ferritin) versus 1/KRel
correlated with R2 = 0.978 (IRP1) and
R2 = 0.991 (IRP2). Frequencies were compared by
nonparametric analysis (2 × 2 table). p values of less
than 0.05 were considered statistically significant.
Thermal Denaturation (Tm)
Experiments--
All thermal denaturation experiments were
performed on a Beckman DU 640 UV-visible spectrophotometer equipped
with a high performance temperature controller and a 6-position
mini-cuvette holder. All measurements were made using 0.350-ml volume
Teflon-stoppered quartz cuvettes with a 1.0-cm light path. To ensure
that RNAs were monomers, melting curves for each RNA were measured
at a range of RNA concentrations (0.1 to 10 µM). All RNAs
appeared to behave as monomers and gave similar melting profiles on
both heating and cooling (data not shown). Data for thermodynamic
curve-fitting analysis were collected on 1.0 µM RNA
samples in 20 mM potassium phosphate (pH 7.5) and 40 mM KCl. Both A260 and
A280 were measured at 0.5 °C intervals as the
temperature was ramped from 18 to 95 °C at a rate of
0.5 °C/min.
Curve-fitting Analysis of Thermal Denaturation Data--
Data
were analyzed using the MeltFit software package designed and provided
by David Draper (31). From the raw absorbance data, the first
derivative of the absorbance versus temperature plot was
determined using the Savitsky-Golay option in MeltFit and was
normalized to the absorbance at 25 °C. In each case except for the
Pavia 2 mutant, fitting of the first derivative curves to four
sequential transitions was performed simultaneously at both 260 and 280 to improve the quality of the fit. From the We used band-shift competition assays to determine the affinities
of IRP1 and IRP2 for IREs containing HHCS mutations. These experiments
measured the ability of the mutant IREs to compete with
33P-labeled wild-type L-ferritin IRE for the
binding of the IRPs, as detected by the gradual disappearance of a
shifted band on the gel in the presence of increasing amounts of
unlabeled competitor. As a control, we included an experiment in which
wild-type L-ferritin IRE was used as the competitor. In
these and all subsequent experiments, we used RNA oligonucleotides that
had been designed to include the first 77 nucleotides of the
L-ferritin transcript in an effort to conserve some of the
natural context of the IRE (Fig.
1a). These constructs differed
from the actual transcript only in lacking the normal 5' cap
modifications and having a G instead of C at the +2 position to permit
efficient translation by T7 RNA polymerase. Gel sections showing the
IRP-shifted band from each experiment have been assembled in Fig.
2. The appearance of the IRP1-shifted band as a fine doublet is the result of changes in the oxidative state
of a disulfide couple that does not affect IRE binding activity (data
not shown).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-33P]UTP (Amersham Pharmacia Biotech), 0.2 µM DNA template, and 2 units/µl T7 RNA polymerase. RNA
was purified as described above except that following isolation from
the gel the RNA was ethanol-precipitated and resuspended in diethyl
pyrocarbonate-treated H2O. The RNA was quantitated and
folded as described above.
3 Prime, Inc., Boulder, CO), 0.15 mg/ml yeast
tRNA, 2 mM dithiothreitol, 25 mM Tris-HCl (pH 7.5), 40 mM KCl, and 0.6 pmol (30 nM) of IRP1
or IRP2. These reactions were incubated at room temperature for 20 min
and then electrophoresed on 10% nondenaturing polyacrylamide gels at
130 V for 4 h. After drying, the gels were exposed to either Kodak
BioMax MR film or a Molecular Dynamics PhosphorImaging screen.
f1)), where [C]free = [C]i
[H]i (f0
f) and represents the amount of unbound competitor RNA; [C]i represents the initial concentration of competitor RNA,
and [H]i represents the initial amount of radiolabeled RNA.
Using Kapp, [H]free (the
concentration of unbound radiolabeled IRE) and the
KD(known) for the wild-type IRE (as previously reported, see Ref. 23), the following equation can be used to determine
KD(comp), the KD of the
competitor RNA: KD(comp) = (KappKD(known))/(KD(known) + [H]free). The relative KD,
KRel, equals
KD(comp)/KD(known). For each HHCS
mutant, KD(comp) is listed as the mean of at least
three separate experiments ±1 S.D. in Table I.

G25(complex) was calculated from
RT ln (KRel).
H and
Tm values of each transition provided by MeltFit, values for both
G25 and
S25 were calculated as
G25 =
H (1
T/Tm) and
S25 = (
H
G25)/T,
where T = 298.15 K, and Tm is the
melting temperature, also expressed in Kelvin. Theoretical values of
G,
H, and
S (at 1 M NaCl) were determined for the wild-type
L-ferritin IRE using the Turner Rules for nearest neighbor
approximation (32).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (22K):
[in a new window]
Fig. 1.
Secondary structures of the L-ferritin IRE
and the consensus IRE. a, the positions of the HHCS
mutations within the L-ferritin IRE are identified in
bold, with the arrow indicating the observed
nucleotide substitution. The numbering of the nucleotide positions is
with respect to the transcriptional start site. Each mutation has been
named using the name of the city in which it was first identified and
characterized (Verona, Verona, Italy; Paris 1 and Paris 2, Paris,
France; London 1 and London 2, London, UK; Pavia 1 and Pavia 2, Pavia,
Italy). The first 77 nucleotides of the L-ferritin
transcript were used throughout these studies; the nucleotide in the +2
position is italicized to indicate that the naturally
occurring C has been replaced with a G to facilitate transcription with
T7 RNA polymerase; b, the sequence and secondary structure
of the consensus IRE. The hexanucleotide loop has the sequence
CAGYGX, where Y = U or A and
X = U, C, or A; C-1 and G-5 of the loop form a
loop-bridging base pair. The upper stem of 5 base pairs is separated
from a lower stem of varying length by an unpaired cytosine.

View larger version (47K):
[in a new window]
Fig. 2.
Band-shift competition assays of IREs
containing HHCS mutations. Band-shift competition experiments were
performed in order to determine the binding affinities
(KD values) of IREs containing HHCS point mutations.
Radiolabeled (33P) wild-type L-ferritin IRE
(0.8 pmol) was incubated with either human IRP1 or human IRP2 (0.6 pmol) in the absence or presence of increasing quantities (0, 0.8, 1.6, 4.0, 8.0, and 80.0 pmol) of unlabeled competitor IRE that contained
either no mutations (wild-type L-ferritin) or a single HHCS
mutation. These samples were electrophoresed on 10% nondenaturing
polyacrylamide gels, and the amount of 33P-labeled IRE in
an IRP-shifted band was measured in each lane. The gels were visualized
by autoradiography and by exposure to a phosphorimaging screen, which
permitted the quantitation of the amount of RNA shifted in each lane.
Sections of each gel containing the IRP-shifted RNA are assembled
above. From these images we can identify mutations that severely reduce
IRE affinity (Verona, Paris 2, and Paris 1), moderately reduce affinity
(London 1, London 2, and Pavia 1), and minimally alter affinity (Pavia
2).
By visual inspection, we can readily distinguish the mutations that most severely impair the ability of the IRE to compete for IRP binding from those that only modestly impair competition. The most ineffective competitors are the Verona, Paris 2, and perhaps Paris 1 mutations. IREs containing these mutations only begin to show significant competition when present at 100-fold excess. Another group of mutations, including London 1, London 2, and Pavia 1, compete effectively at somewhat lower concentrations, between 5- and 10-fold excess. In contrast, the Pavia 2 mutation nearly rivals the wild-type L-ferritin IRE in its ability to compete for binding. Qualitatively, the competition profile for each mutation appears to be similar for both IRPs.
To characterize further these mutations, we quantitated the amounts of shifted and unshifted RNA in each of the competition experiments. By using the previously determined KD values for the interactions of a consensus IRE with IRP1 (50 pM) or IRP2 (30 pM) (23), we were able to calculate the KD values of each mutant IRE, and the ratio of the KD(mutant) to KD(wild type), expressed as KRel (Table I). By this method, KRel >1 indicates weaker binding, whereas KRel <1 indicates stronger binding. The KD values calculated in control competition experiments with wild-type L-ferritin were 50 ± 2 pM for IRP1, and 41 ± 2 pM for IRP2, in good agreement with the previously reported values. The Verona mutation had the lowest affinity for both IRP1 and IRP2, with KD values of about 109 (2200-fold reduction) and 9.1 nM (220-fold reduction), respectively. The Paris 2 mutation also showed large reductions in affinity, 620-fold for IRP1 and 220-fold for IRP2. Although the Pavia 1 and Paris 2 mutations involve the same nucleotide position, immediately 5' of the conserved unpaired cytosine, the Pavia 1 mutation is less deleterious to binding. The Paris 1 mutation caused a 220-fold reduction in affinity for IRP1 but had a somewhat more modest effect on IRP2, with only an 83-fold change in KD. Both of the London 1 and London 2 mutations retained modest affinities for the IRPs. The KD values of the IRPs for the Pavia 2 mutant differed from the wild-type affinities by less than 2-fold, similar to the those measured for a wild-type L-ferritin IRE truncated immediately below the C23:G57 base pair (see Fig. 1b; KD and KRel for the truncated IRE are listed in Table I, but the corresponding gel slices are not shown in Fig. 2). One striking pattern that emerged from the measurement of the KD values is that each mutation appears to diminish affinity for IRP1 affinity more than for IRP2. However, the arrangement of the mutations from highest to lowest affinity remains the same for either protein.
|
Data regarding the serum ferritin in HHCS patients was compiled from
several sources (1-12). For both IRP1 and IRP2, we plotted the
KRel of each mutation versus its
clinically measured values of serum ferritin (Fig.
3), and in both cases there appeared to be a correlation. Nonlinear regression analysis (regression of ln
(serum ferritin) versus 1/KRel)
showed that there was a significant relationship between serum ferritin
and KRel values of both IRP1 and IRP2. As Fig. 3
illustrates, serum ferritin levels vary dramatically among patients
with the same mutation or even within a single patient on different
occasions. Yet we noticed that the greatest serum ferritin for each
mutation, denoted as max ferritin and appearing in Fig. 3 as
filled circles, appears to be strongly linked to
KRel. Therefore, we performed regression
analysis of ln (max ferritin) versus
1/KRel and found further evidence of a
correlation for both IRP1 and IRP2.
|
The absence of a quantitative measurement for the severity of cataract
in HHCS patients made it difficult to establish any clear relationship
between variations in KRel and severity of cataract. We therefore defined cataract as severe when there was a
marked loss in visual acuity in the 1st decades (with some individuals requiring surgery), mild when the defect in visual acuity could be
corrected with the use of appropriate eyeglasses, and asymptomatic when
it did not impair visual acuity. By using nonparametric analysis, values of KRel(IRP1) <100 and
KRel(IRP2) <80 were significantly associated
with asymptomatic to mild cataract, whereas
KRel(IRP1) >100 or
KRel(IRP2) >80 were found in association with
mild to severe cataract (
2 = 29.68, p < 0.00001). The characteristics of each mutation are summarized in Table
II.
|
Because the consensus IRE has both conserved primary sequence elements
and conserved secondary structure elements, we realized that reductions
in affinity in HHCS could be caused by the elimination of a
sequence-specific contact (hydrogen bonding, van der Waals contacts,
electrostatic interactions), the perturbation of the secondary
structure or stability of the IRE (structure-specific effects), or a
combination of both. The destabilization of the complex with respect to
the wild-type association can be expressed in terms of

G25(complex) and is readily calculated
from RT ln KRel such that decreases
in affinity appear as positive values. The change in free energy of the
complexes ranged from 0.2 to 4.6 kcal/mol for IRP1 and 0.3 to 3.2 kcal/mol for IRP2 (Table I). The change in IRE·IRP complex stability
should be reflected by the sum of changes in specific intermolecular
interactions and changes in the stability of the IRE, which can be
expressed as 
G25(IRE). In an effort to
understand some of these contributions, we used UV thermal denaturation
experiments and the fitting of sequential transitions to the resulting
melting curves to determine 
G25(IRE)
(31).
The absorbance of each IRE was monitored at both 260 and 280 nm as the
temperature was increased from 18 to 95 °C. From the change in
absorbance as a function of temperature, we calculated the first
derivative with respect to temperature
(
A/
T), and we plotted this
versus temperature to yield the melting curves shown in Fig.
4. The predicted total
G,
H, and
S for the L-ferritin IRE
using the Turner Rules (32) and the secondary structure depicted in
Fig. 1 are as follows:
H =
288.2 kcal/mol,
S =
819 e.u., and
G =
27.8
kcal/mol. Because the helical portion of the L-ferritin IRE
used here is periodically interrupted by unpaired nucleotides, we
expected these IREs to denature as a series of discrete domains and
that these would appear as overlapping sequential transitions in the
melting profiles. Although we were uncertain about the number of
transitions to expect in the unfolding of our IREs, fitting of the
melting curve of the wild-type L-ferritin IRE to four
sequential transitions yielded total
H and
G values that were in closest agreement to the predicted
values (
H = 274 kcal/mol and
G25 = 29.6 kcal/mol). From our denaturation
experiments,
H,
G, and
S are
reported as positive values.
|
We used the following strategy to assign each melting transition to a
specific portion of the IRE: transitions in which the Tm was significantly affected by a mutation were
assigned to a region that included that site and contained enough
secondary structure to approximately match the
H
determined by the curve-fitting analysis. If a mutation produced a
Tm change in more than one transition, the
transition that was most affected was matched with the region
containing that mutation, and the other affected transitions were
assigned to adjacent domains. Analysis of the melting curves of each of
the mutants (with the exception of the Pavia 2 mutant) yielded two
transitions for which the Tm and
H
remained essentially unchanged, one transition that showed changes in
Tm and
H for mutations that occurred
in both the upper stem and loop (Paris 1, London 1, London 2), and a
fourth transition that predominantly showed changes when the mutations occurred in the vicinity of the bulged C (Paris 2, Pavia 1) (Fig. 5a). This pattern allowed us
to confidently pair the transition at Tm = 48.5 °C (T1) with the region just below the bulged C and the
transition at Tm = 58.6 °C (T2) with the upper stem and loop (Fig. 5b). Although the precise regions
corresponding to the transitions at 60.7 °C (T3) and 67.9 °C (T4)
are difficult to assign because of the shortage of mutational
information from that part of the IRE, the dramatic change in the T4
portion of the melting curve of Pavia 2 (Fig. 4, Pavia 2 panel) suggests that T4 includes the helix (C18:G62 to U26:A54) in
which the Pavia 2 mutations occur. The thermodynamic parameters derived
from each RNA are listed in Table III.
Because we were uncertain of the changes in secondary structure in the
Pavia 2 mutant, we were unable to derive thermodynamic information from
the Pavia 2 melting curve.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Among the numerous genetic disorders that have been identified and studied, HHCS has emerged as a novel disease that arises from mutations within the protein-binding site of an RNA regulatory element. The mutations associated with HHCS occur throughout the IRE of the L-ferritin transcript and are so far the only naturally occurring mutations known to disrupt IRP recognition in a living organism. The clinical severity of HHCS is remarkably varied; serum ferritin levels can range anywhere from 2- to 10-fold higher than normal, and lens opacities can be severe enough to require surgical intervention or mild enough to have no detectable effect on visual acuity.
The measurements of the in vitro affinities of IRP1 and IRP2 for IREs containing HHCS mutations revealed that these mutations had variable effects on IRP binding. Relative dissociation constants ranged from 1.5 (Pavia 2) to 2200.0 (Verona) for IRP1, for a nearly 1500-fold difference in effect, and from 1.7 (Pavia 2) to 220.0 (Verona) for IRP2, or a 130-fold difference. We also found that with every mutation, except Pavia 2, the affinity for IRP1 was more affected than for IRP2. Studies of nonconsensus IRP-binding sequences have shown that, in general, IRP2 has a greater tolerance for mutations within the hexanucleotide loop of the IRE (23, 24). Additionally, the IRE binding capacity of IRP2 is much less affected by mutagenesis of individual arginines within the putative IRE-binding site (23). The diminished sensitivity of IRP2 to IRE mutations is further highlighted by the effects of the HHCS mutations, although the ranking of the HHCS mutations from lowest to highest affinity remains the same for both IRPs.
The reported concentration of serum ferritin for each HHCS mutation covers a wide range and may reflect the influence of non-HHCS factors, such as inflammation, cancer, and pathogenic infection, that are known to affect ferritin expression (33). We anticipated that this variability might mask correlations between binding affinity and serum ferritin levels; yet we discovered a significant correlation between serum ferritin levels and KRel for both IRPs and an even stronger correlation between the KRel and maximum serum ferritin. With such strong correlations for both IRPs, these experiments do not identify either protein as the predominant contributor to HHCS. The sharp transition from low (wild-type and Pavia 2) to relatively high (London 1) maximum serum ferritin with increasing KRel implies that the affinity of the IRPs for the IRE is highly optimized for the consensus sequence. Even the appearance of a measurable difference in serum ferritin for patients with the weakly impaired Pavia 2 mutation illustrates the extreme sensitivity of the IRE-IRP system to slight perturbations in affinity. With regard to cataract, there also appears to be a correlation between cases of HHCS requiring surgical intervention and mutations with the largest values of KRel. More subtle correlations between KRel and severity might easily be masked by other genetic or environmental factors thought to influence cataractogenesis, including differences in diet, exposure to UV light, or substance abuse (34).
Despite the correlation between serum ferritin levels and the effect of each HHCS mutation on the binding of IRPs, the mechanism by which L-ferritin reaches the serum is unclear. Ferritin appears in human serum even under normal conditions, and consists predominantly, if not exclusively, of L-ferritin (35). There have also been reports of glycosylated forms of ferritin in the serum (36, 37), implicating a secretory origin for a portion of serum ferritin. Although neither L- or H-ferritin has a classical signal peptide for targeting the nascent protein to the endoplasmic reticulum, L-ferritin has a short stretch of hydrophobic residues near the N terminus that might permit translocation to the ER. Several studies have detected elevated intracellular levels of L-ferritin in cell lines and cultured tissues from HHCS patients (7, 38), suggesting that both the intracellular and serum forms of L-ferritin are expressed from the same misregulated gene. It is possible that when L-ferritin is translated in serum monocytes it is partitioned into both the ER and the cytosol and that the ER fraction is secreted into the serum. This partitioning could also serve as an additional point of regulation and might explain some of the variation in levels of serum ferritin in HHCS patients. The mechanism leading to cataract formation is also unknown, but a recent study has suggested that it might involve perturbations of the redox status of the lens (38).
We also wondered what these mutations might reveal about the structure
of the IRE and its interactions with the IRPs. Although little is known
about the three-dimensional structure of IRP1 or IRP2 (39), there has
been some success determining the structure of the consensus IRE.
Unfortunately, it has been difficult to ascertain which aspects of the
secondary and tertiary structure of the IRE are important for
recognition by the IRPs, nor have the sites of any intermolecular
contacts been firmly identified. In studies of the consensus IRE (22),
the effects of single point mutations on IRP affinity have been
measured in an effort to identify sites of contact. Although measurable
effects may indicate the loss of base-specific contacts, they might
also reflect changes in the stability or secondary structure of the
IRE. We recognized that some of the HHCS mutations might also act by
disrupting important secondary structural elements of the IRE,
including the A-form helix of the lower stem (Paris 2, Pavia 1, and
Pavia 2), the extra-helical conformation of the bulged cytosine (Paris 2 and Pavia 1), the A-form helical conformation of the upper stem (London 2), the intraloop base pair (London 1), and the base-stacking interactions within the loop (Paris 1) (27-29). To elucidate any effects of the HHCS mutations on the structural conformation of the
IRE, we measured the melting curves of the mutant IREs and calculated
differences in their thermodynamic stabilities as reflected by

G25(IRE). The comparison of these changes
with 
G25(complex) allowed us to begin to
understand the effects of many of the HHCS mutations.
The Verona mutation caused the largest loss in affinity for IRP1 and
IRP2; yet its melting curve and the thermodynamic stability were nearly
identical to the wild-type sequence, with a

G25(IRE) of only 0.5 kcal/mol. NMR
analyses of the IRE have shown that the guanosine normally found at
this position is solvent-exposed and structurally dynamic (25, 27), and
cleavage assays have identified this position as being particularly
sensitive to chemical reagents (40, 41). These observations, together
with the thermodynamics of the Verona mutant, suggest that the
consensus guanosine in that position is involved in an interaction with
the IRPs worth between 2.8 and 4.1 kcal/mol.
The Paris 1 mutation also had relatively little effect on the
energetics of the IRE loop, producing a

G25(IRE) that is insufficient to account
for all of 
G25(complex) for either IRP. In
the consensus IRE, the adenine normally found at this position has been
shown to be stacked on top of the intra-loop C1-G5 base pair (25). Replacement of the consensus adenine with guanosine might alter the
orientation of this stacking interaction, but such a change is unlikely
to produce a large 
G25(complex). Although
SELEX experiments have confirmed the preference for adenosine at this site, one study found cytidine in several IRP-binding clones and guanosine in a single IRP2-specific sequence containing multiple nonconsensus nucleotides (23), whereas the other identified cytidine-
and uridine-containing sequences (24). The tolerance of substitutions
other than guanosine at this site suggests that this nucleobase may be
involved in a stacking interaction with the IRP and that the large size
of guanosine may disrupt this association under most conditions. Such
an interaction could account for the observed changes in affinity and
leaves open the possibility that this base becomes unstacked in the
IRE·IRP complex.
The London 1 mutation occurs in the position that has been shown by NMR
to form a base pair with the fifth nucleotide in the hexaloop (25, 26).
The mutation of C-39 to a U would eliminate Watson-Crick pairing with
G-5 but would still permit the formation of a U-G base pair. We would
expect this interaction to be weaker than the normal C-G base pair, an
expectation that was confirmed by a drop in the
Tm(T2) of 4.3 °C and a corresponding 
G25(IRE) of 1.2 kcal/mol. This is nearly
identical to the 
G25(complex) for both
IRP1 (1.3 kcal/mol) and IRP2 (1.0 kcal/mol). Thus, it is likely that
most of the destabilization of the London 1 IRE·IRP complex arises
from the weakened base pairing interaction, which leads in turn to a
less favorable entropy change upon binding of the IRP.
The London 2 mutation might be expected to lead to a loss of base
pairing, with the subsequent destabilization of the T2 domain. It does
cause a drop in Tm(T2), plus a small loss in Tm(T1), but causes a

G25(IRE) of only 0.2 kcal/mol resulting
from a gain in enthalpy of 10 kcal/mol and an entropic penalty of
34 e.u. In this mutant, the upper portion of the IRE could adopt
an alternative conformation in which U-34 through C-39 pair with G-43
through G-48. This alternative secondary structure would be predicted
to have an increase of 15 kcal/mol in
H and 0.2 kcal/mol
in
G in comparison to the consensus fold and would place
C-33 in a mismatch with A-49. Although the predicted energies of such a
fold are in close agreement to what we measured, it seems likely that
such a dramatic rearrangement would more severely impair the binding of
IRPs. An alternative possibility is that this mutation forms a
non-Watson-Crick A:G base pair that allows the preservation of the
upper stem. The mismatch would probably distort the normal A-form helix
geometry, and might force one of the A:G bases into a
syn-glycosidic conformation (42, 43). A recent report has
identified a nonfunctional IRE in the mouse glycolate oxidase
transcript that has an A:A mismatch at the same site (44). In that
example, the putative IRE retains its affinity for IRPs at room
temperature but loses virtually all affinity at 37 °C. The London 2 mutant, however, binds poorly even at 25 °C, despite the minimal
effects on 
G25(IRE). From the sequences of
naturally occurring IREs, we know that there is no discernible base
pair preference in the upper stem, but there may be IRP contacts involving the RNA backbone. The changes in helix geometry arising from
an A:G mismatch may be sufficient to disrupt backbone contacts and
account for the loss in binding affinity.
Both of the Paris 2 and Pavia 1 mutations give rise to moderate values
of 
G25(IRE) (1.1 and 1.7 kcal/mol,
respectively). Yet, the Paris 2 mutation causes a much larger

G25(complex). It has been shown that the
unpaired cytosine normally adopts an extrahelical conformation and is
structurally dynamic (25) and that the tendency of an unpaired
nucleotide to stack within the helix is dependent upon the sequence of
adjacent base pairs (45). Therefore, we might expect these mutations to
alter the stacking preferences of the otherwise bulged C-33. We found
that the 
H(T1) of 10 kcal/mol for the Paris 2 mutation
is accompanied by an increase in
H(T2) of 7 kcal/mol,
suggesting that a stacking interaction has shifted from the T2 domain
to the T1 domain. This may indicate that the normally bulged C-33 has
adopted an intrahelical, stacked conformation. Such a conformational
change would mask the identity of the highly conserved C-33 and may
prevent the formation of intermolecular contacts. The energy required
to extrude C-33 from the helix may account for a portion of

G25(complex). Although the Pavia 1 mutant
also has a similar decrease in
H(T1), the absence of a
compensatory change in
H(T2) makes it less likely that
the extrahelical conformation of C-33 is being altered.
Perhaps the most dramatic result from the thermal denaturation studies is the change in the melting curve profile of the Pavia 2 mutant. Despite the retention of near wild-type affinity for both IRP1 and IRP2, the melting curve suggests a complete change in the thermodynamic behavior of this RNA. Analysis of the predicted lowest energy secondary structures of the Pavia 2 IRE shows that the energy differences between the fold assumed in this study and alternate folds are much smaller than with the wild-type sequence (data not shown). Because the two mutations in this sequence are outside of the recognized IRP binding footprint (39), it is also unlikely that direct contacts are being lost. One possibility is that changes in the stability of the lower region of the IRE result in an altered fold of the RNA that retains the appropriate secondary structure in the IRP-binding regions of the IRE sequence.
The Pavia 2 mutation illuminates what might be the primary function of the lower stem of the IRE. The thermodynamic behavior of Pavia 2 indicates that the IRP-binding domain, comprised of T1 and T2 in this study, is intact and sufficiently stable to retain the secondary structure required for functional activity. The lower stem serves as an additional regulatory element in that its length and G-C content fine-tune the stability of the IRE, modulating the sensitivity of a transcript to IRP-mediated translational control. This model is supported by studies showing that the translation of ferritin is more sensitive to changes in cellular iron status than mitochondrial aconitase, which has a shorter, A-U rich lower stem in its IRE (46).
The recent discovery and characterization of hereditary
hyperferritinemia-cataract syndrome has provided a unique opportunity to understand the effects of IRE mutations on the behavior of the IRP
regulatory process in a living organism. The diversity of HHCS-causing
mutations is remarkable, and we speculate that many more HHCS mutations
will eventually be found. As the medical community continues to
identify new mutations, it will be important to note those nucleotide
positions that never seem to be affected in HHCS. We believe that there
may be naturally occurring polymorphisms within the
L-ferritin IRE that do not affect IRP binding, or perhaps some that enhance binding, but the absence of a known phenotype will
make it difficult to identify such variations. For each new mutation
that does affect IRP binding, however, we can perform similar
thermodynamic analyses and further refine our understanding of the
exquisite recognition of IREs by IRP1 and IRP2.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants from MURST, Rome, and IRCCS Policlinico S. Matteo, Pavia (to M. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Bldg. 18T, Rm. 101, NICHD, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-6368; Fax: 301-402-0078; E-mail: trou@helix.nih.gov.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: HHCS, hereditary hyperferritinemia-cataract syndrome; IRE, iron-responsive element; IRP, iron regulatory protein; ER, endoplasmic reticulum.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Girelli, D., Oliviero, O., De Franceschi, L., Corrocher, R., Bergamaschi, G., and Cazzola, M. (1995) Br. J. Haematol. 90, 931-934[Medline] [Order article via Infotrieve] |
| 2. | Bonneau, D., Winter-Fuseau, I., Loiseau, M.-N., Amati, P., Berthier, M., Oriot, D., and Beaumont, C. (1995) J. Med. Genet. 32, 778-779[Medline] [Order article via Infotrieve] |
| 3. | Beaumont, C., Leneuve, P., Devaux, I., Scoazec, J.-Y., Berthier, M., Loiseau, M.-N., Grandchamp, B., and Bonneau, D. (1995) Nat. Genet. 11, 444-446[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Girelli, D.,
Corrocher, R.,
Bisceglia, L.,
Olivieri, O.,
De Franceschi, L.,
Zelante, L.,
and Gasparini, P.
(1995)
Blood
86,
4050 |
| 5. |
Aguilar-Martinez, P.,
Biron, C.,
Masmejean, C.,
Jeanjean, P.,
and Schved, J.-F.
(1996)
Blood
88,
1895 |
| 6. | Merkt, J. D. (1997) Dtsch. Med. Wochenschr. 122, 504-506[Medline] [Order article via Infotrieve] |
| 7. |
Cazzola, M.,
Bergamaschi, G.,
Tonon, L.,
Arbustini, E.,
Grasso, M.,
Vercesi, E.,
Barosi, G.,
Bianchi, P. E.,
Cairo, G.,
and Arosio, P.
(1997)
Blood
90,
814-821 |
| 8. |
Girelli, D.,
Corrocher, R.,
Bisceglia, L.,
Olivieri, O.,
Zelante, L.,
Panozzo, G.,
and Gasparini, P.
(1997)
Blood
90,
2084-2088 |
| 9. |
Arnold, J. D.,
Mumford, A. D.,
Lindsay, J. O.,
Hegde, U.,
Hagan, M.,
and Hawkins, J. R.
(1997)
Gut
41,
408-410 |
| 10. |
Martin, M. E.,
Fargion, S.,
Brissot, P.,
Pellat, B.,
and Beaumont, C.
(1998)
Blood
91,
319-323 |
| 11. |
Mumford, A. D.,
Vulliamy, T.,
Lindsay, J.,
and Watson, A.
(1998)
Blood
91,
367-368 |
| 12. |
Cicilano, M.,
Zeccgina, G.,
Roetto, A.,
Bosio, S.,
Infelise, V.,
Stefani, S.,
Mazza, U.,
and Camaschella, A.
(1999)
Haematologica
84,
489-492 |
| 13. | Harrison, P. M., and Arosio, P. (1996) Biochim. Biophys. Acta 1275, 161-203[Medline] [Order article via Infotrieve] |
| 14. | Klausner, R. D., Rouault, T. A., and Harford, J. B. (1993) Cell 72, 19-28[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Hentze, M. W.,
and Kuhn, L. C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8175-8182 |
| 16. | Gray, N. K., and Hentze, M. W. (1994) EMBO J. 13, 3882-3891[Medline] [Order article via Infotrieve] |
| 17. | Muckenthaler, M., Gray, N. K., and Hentze, M. W. (1998) Mol. Cell 2, 383-388[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Rouault, T. A., and Klausner, R. D. (1996) J. Bioinorg. Chem. 1, 494-499[CrossRef] |
| 19. | Hentze, M. W., and Kühn, L. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8175-8182 |
| 20. | Iwai, K., Klausner, R. D., and Rouault, T. A. (1995) EMBO J. 14, 5350-5357[Medline] [Order article via Infotrieve] |
| 21. |
Guo, B.,
Phillips, J. D., Yu, Y.,
and Leibold, E. A.
(1995)
J. Biol. Chem.
270,
21645-21651 |
| 22. |
Jaffrey, S. R.,
Haile, D. J.,
Klausner, R. D.,
and Harford, J. B.
(1993)
Nucleic Acids Res.
21,
4627-4631 |
| 23. |
Butt, J.,
Kim, H.-Y.,
Basilion, J. P.,
Cohen, S.,
Iwai, K.,
Philpott, C. C.,
Altschul, S.,
Klausner, R. D.,
and Rouault, T. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
4345-4349 |
| 24. |
Henderson, B. R.,
Menotti, E.,
and Kühn, L. C.
(1996)
J. Biol. Chem.
271,
4900-4908 |
| 25. | Addess, K. J., Basilion, J. P., Klausner, R. D., Rouault, T. A., and Pardi, A. (1997) J. Mol. Biol. 274, 72-83[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Laing, L. G., and Hall, K. B. (1996) Biochemistry 35, 13586-13596[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Hall, K. B., and Tang, C. (1998) Biochemistry 37, 9323-9332[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Milligan, J. F.,
Groebe, D. R.,
Witherell, G. W.,
and Uhlenbeck, O. C.
(1987)
Nucleic Acids Res.
15,
8783-8798 |
| 29. |
Samaniego, F.,
Chin, J.,
Iwai, K.,
Rouault, T. A.,
and Klausner, R. D.
(1994)
J. Biol. Chem.
269,
30904-30910 |
| 30. | Drake, S. K., Lee, K. L., and Falke, J. J. (1996) Biochemistry 35, 6697-6705[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Draper, D. E., and Gluick, T. C. (1995) Methods Enzymol. 259, 281-305[Medline] [Order article via Infotrieve] |
| 32. | Serra, M. J., and Turner, D. H. (1995) Methods Enzymol. 259, 242-261[Medline] [Order article via Infotrieve] |
| 33. | Lee, M. H., and Means, R. T. (1995) Am. J. Med. 98, 566-571[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Trudo, E. W., and Stark, W. J. (1998) Postgrad. Med. 103, 114-116 |
| 35. | Santambrogio, P., Cozzi, A., Levi, S., and Arosio, P. (1987) Br. J. Haematol. 65, 235-237[Medline] [Order article via Infotrieve] |
| 36. | Cragg, S. J., Wagstaff, M., and Worwood, M. (1981) Biochem. J. 199, 565-571[Medline] [Order article via Infotrieve] |
| 37. | Santambrogio, P., Cozzi, A., Levi, S., and Arosio, P. (1987) Br. J. Haematol. 65, 235-237 |
| 38. |
Levi, S.,
Girelli, D.,
Perrone, F.,
Pasti, M.,
Beaumont, C.,
Corrocher, R.,
Albertini, A.,
and Arosio, P.
(1998)
Blood
91,
4180-4187 |
| 39. |
Basilion, J. P.,
Rouault, T. A.,
Massinople, C. M.,
Klausner, R. D.,
and Burgess, W. H.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
574-578 |
| 40. | Thorp, H. H., McKensie, R. A, Lin, P.-N., Walden, W. E., and Theil, E. C. (1996) Inorg. Chem. 35, 2773-2779[CrossRef] |
| 41. | Ciftan, S. A., Theil, E. C., and Thorp, H. H. (1998) Chem. Biol. 5, 679-687[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Morse, S. E.,
and Draper, D. E.
(1995)
Nucleic Acids Res.
23,
302-306 |
| 43. | Gautheret, D., Konings, D., and Gutell, R. R. (1994) J. Mol. Biol. 242, 1-8[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Kohler, S. A., Menotti, E., and Kühn, L. C. (1999) J. Biol. Chem. 274, 2401-2407 |